Zablocka Tatjana, Nikolajeva Anna, Kreismane Madara, Pjanova Dace, Isajevs Sergejs
Department of Pathology, Faculty of Medicine, University of Latvia, LV-1004 Riga, Latvia.
Riga East University Hospital, Centre of Pathology, LV-1038 Riga, Latvia.
Mol Clin Oncol. 2021 Dec;15(6):255. doi: 10.3892/mco.2021.2417. Epub 2021 Oct 8.
Tumor-infiltrating lymphocytes (TILs) in primary cutaneous melanoma are considered to represent the host's antitumor immunological response; however, whether there are associations between TIL grade and histopathological characteristics and disease survival remains controversial. BRAF mutational status has been established as a routine screening method in advanced malignant melanoma, and worse prognosis rates have been demonstrated in patients harboring BRAF mutations. However, the general impact of BRAF mutational status on survival and histopathological characteristics is still debated. The aim of the present study was to compare the value of the assessment of TIL grade in stages I-II nodular and superficial spreading melanoma and BRAF mutational status, and its influence on clinicopathological characteristics. Altogether, 85 patients at stage IA-IIC who underwent melanoma surgical treatment at the Riga East University Hospital between 2012 and 2017 were retrospectively enrolled in the study. The histopathological characteristics were assessed according to the current World Health Organization and The American Joint Committee on Cancer 8th edition guidelines. The current study showed that patients with melanoma with high TIL grade had significantly better progression-free survival than patients with low TIL grade (hazard ratio, 4.9; 95% CI, 2.3-11.2; P<0.0001). BRAF mutations were observed in 52 patients (61.2%). BRAF mutational status in melanoma was associated with Clark invasion level (P=0.045), patient age (P=0.02) and TIL (P=0.04). The assessment of TIL grade in stage I-II melanoma demonstrated prognostic significance value and may help improve risk assessment in the future.
原发性皮肤黑色素瘤中的肿瘤浸润淋巴细胞(TILs)被认为代表宿主的抗肿瘤免疫反应;然而,TIL分级与组织病理学特征及疾病生存率之间是否存在关联仍存在争议。BRAF突变状态已成为晚期恶性黑色素瘤的常规筛查方法,携带BRAF突变的患者预后较差。然而,BRAF突变状态对生存率和组织病理学特征的总体影响仍存在争议。本研究的目的是比较I-II期结节型和浅表扩散型黑色素瘤中TIL分级评估和BRAF突变状态的价值,及其对临床病理特征的影响。2012年至2017年期间,共有85例IA-IIC期黑色素瘤患者在里加东大学医院接受了手术治疗,并被回顾性纳入本研究。根据世界卫生组织和美国癌症联合委员会第8版指南评估组织病理学特征。本研究表明,TIL分级高的黑色素瘤患者的无进展生存期明显优于TIL分级低的患者(风险比,4.9;95%CI,2.3-11.2;P<0.0001)。52例患者(61.2%)检测到BRAF突变。黑色素瘤中的BRAF突变状态与Clark浸润水平(P=0.045)、患者年龄(P=0.02)和TIL(P=0.04)相关。I-II期黑色素瘤中TIL分级的评估具有预后意义,可能有助于未来改善风险评估。